STATISTICAL BRIEF #200 |
January 2016
Marguerite L. Barrett, M.S., Audrey J. Weiss, Ph.D., Carol Stocks, Ph.D., R.N., Claudia A. Steiner, M.D., M.P.H., and Evan R. Myers, M.D., M.P.H. Introduction By the age of 50, as many as 70-80 percent of women will develop uterine fibroids (leiomyomas)—typically benign tumors of the uterus.1,2 For many women, uterine fibroids pose no health risks and women are asymptomatic. For others, uterine fibroids may cause symptoms such as heavy bleeding, pain, and frequent urination, and they are associated with an increased risk of pregnancy complications.3 Some women are more likely than others to develop uterine fibroids. For instance, uterine fibroids are more common in Black than in White women,4 and Black women tend to have more severe symptoms.5 Research also indicates that, compared with White women, Black women develop uterine fibroids at a younger age and have more severe fibroids (e.g., larger size, number, and growth rate).6,7,8 For women with symptomatic fibroids, a variety of treatment options are available.9 Women with mild symptoms may choose medical treatments such as pain relievers and hormonal drugs. Those with moderate to severe symptoms may need surgery to treat uterine fibroids. Common surgical treatment options include hysterectomy (removing the uterus), myomectomy (removing the fibroids), uterine fibroid embolization (blocking the blood supply to the fibroids), and endometrial ablation (removing the lining of the uterus, which controls bleeding without directly affecting the fibroids). This Healthcare Cost and Utilization Project (HCUP) Statistical Brief presents data on four surgical procedures to treat benign uterine fibroids among women aged 18-54 years in two hospital settings: hospital inpatient and hospital-based ambulatory surgery. Our analysis is limited to hospitals within 13 States—representing more than one-fourth of the U.S. population—that included data on surgical treatment of benign uterine fibroids in the inpatient and ambulatory surgery settings. We focus on four common surgical treatments of benign uterine fibroids: hysterectomy, myomectomy, uterine fibroid embolization, and endometrial ablation. An overview of characteristics of women with benign uterine fibroids who underwent one of these surgical treatments in 2013 is provided by hospital setting. We present trends in the four surgical procedures to treat benign uterine fibroids by hospital setting from 2005 through 2013. The distribution of these four procedures by patient race/ethnicity and expected primary payer in each hospital setting is provided for 2013. Only differences of at least 10 percent are noted in the text. Findings Characteristics of hospitalizations for benign uterine fibroids, 2013 Table 1 presents characteristics of hospitalizations for benign uterine fibroids treated with four common procedures in the hospital inpatient compared with the hospital-based ambulatory surgery setting in 2013. |
|
Table 1. Characteristics of hospitalization for benign uterine fibroids by setting, in 13 States, 2013 | ||
Characteristic | Inpatient surgery | Hospital-based ambulatory surgery |
---|---|---|
Hospital stay characteristics | ||
Total number of cases | 25,500 | 23,360 |
Length of stay, mean days | 2.3 | 0.6 |
Mean hospital charges,a $ | 28,000 | 25,200 |
Patient characteristics | ||
Mean age, years | 43.3 | 43.4 |
Age in years, % | ||
18-24 | 0.4 | 0.3 |
25-34 | 9.6 | 9.0 |
35-44 | 43.0 | 42.6 |
45-54 | 47.0 | 48.0 |
Race/ethnicity, % | ||
White | 33.9 | 51.4 |
Black | 40.3 | 27.8 |
Hispanic | 9.8 | 5.8 |
Otherb | 9.7 | 6.8 |
Missing/Invalidc | 6.3 | 8.2 |
Expected primary payer, % | ||
Medicaid | 17.7 | 10.6 |
Private | 70.1 | 80.4 |
Uninsured | 6.3 | 3.2 |
Otherd | 5.9 | 5.2 |
Missing/Invalid | 0.1 | 0.4 |
Community-level income, % | ||
Lowest income quartile | 24.8 | 21.2 |
All other income quartiles | 75.2 | 78.8 |
Treatment characteristics | ||
Procedure type, % | ||
Hysterectomy | 76.5 | 66.8 |
Myomectomy | 21.9 | 22.1 |
Uterine fibroid embolization | 1.6 | 6.7 |
Endometrial ablation | 0.1 | 4.3 |
Note: Analysis was limited to cases of benign uterine fibroids treated with one of the four selected surgical procedures. a We report hospital charges rather than costs because Cost-to-Charge Ratios are not available for ambulatory surgery data. b Other race/ethnicity includes Asian, Pacific Islander, and American Indian. c Two of the 13 States included in this analysis did not report race/ethnicity information. d Other expected primary payer includes Medicare. Source: Agency for Healthcare Research and Quality (AHRQ), Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project (HCUP), State Inpatient Databases (SID) and State Ambulatory Surgery and Services Databases (SASD) from 13 States, 2013 |
Figures 1 and 2 present the rate of discharges per 100,000 females in the population, aged 18-54 years, who had a hysterectomy, myomectomy, uterine fibroid embolization, or endometrial ablation to treat benign uterine fibroids in the hospital inpatient setting compared with the hospital-based ambulatory surgery setting, from 2005 through 2013. |
Figure 1. Rate of hysterectomy and myomectomy to treat benign uterine fibroids by hospital setting, in 13 States, 2005-2013
Abbreviations: AS, ambulatory surgery Figure 1 is a line graph that shows the rate of hysterectomy and myomectomy to treat benign uterine fibroids in females aged 18-54 years in inpatient surgery and ambulatory surgery hospital settings in 13 States from 2005 through 2013. The rate of hysterectomy per 100,000 population in the inpatient surgery hospital setting declined steadily from 196.2 in 2005 to 93.3 in 2013. The rate of hysterectomy per 100,000 population in the ambulatory surgery hospital setting increased steadily from 14.6 in 2005 to 74.7 in 2013. The rate of myomectomy per 100,000 population in the inpatient surgery hospital setting declined from 37.6 in 2005 to 26.7 in 2013. The rate of myomectomy per 100,000 population in the ambulatory surgery hospital setting declined steadily from 22.7 in 2005 to 16.0 in 2009 and then increased to 24.7 in 2013.
|
|
Figure 2. Rate of uterine fibroid embolization and endometrial ablation to treat benign uterine fibroids by hospital setting, in 13 States, 2005-2013
Abbreviations: AS, ambulatory surgery; UFE, uterine fibroid embolization Figure 2 is a line graph that shows the rate of uterine fibroid embolization and endometrial ablation to treat benign uterine fibroids in females aged 18-54 years in inpatient surgery and ambulatory surgery hospital settings in 13 States from 2005 through 2013. The rate of uterine fibroid embolization per 100,000 population in the inpatient hospital setting increased from 0.7 in 2005 to 1.4 in 2009, declined to 0.6 in 2011, and then increased to 1.9 in 2013. The rate of uterine fibroid embolization per 100,000 population in the ambulatory surgery hospital setting increased from 2.8 in 2005 to 6.4 in 2009; it continued to increase but more slowly to 7.5 in 2013. The rate of endometrial ablation per 100,000 population in the inpatient hospital setting increased from 0.15 in 2005 to 0.18 in 2007 and then declined steadily to 0.09 in 2013. The rate of endometrial ablation per 100,000 population in the ambulatory surgery setting declined from 5.9 in 2005 to 5.1 in 2009, increased to 5.5 in 2011, and declined to 4.8 in 2013.
|
|
Figure 3. Distribution of surgical procedures to treat benign uterine fibroids by hospital setting, in 13 States, 2013
Notes: Open hysterectomy and myomectomy involve removing the uterus or fibroids through an abdominal incision. Laparoscopic hysterectomy and myomectomy utilize a telescopic camera and surgical tools inserted through small abdominal incisions. Vaginal hysterectomy is performed through the vagina. Figure 3 is a bar chart that shows the distribution of surgical procedures to treat benign uterine fibroids in inpatient surgery and ambulatory surgery settings in 13 States in 2013. Of 15,182 open hysterectomies performed, 97.3% were in the inpatient surgery hospital setting and 2.7% were in the ambulatory surgery hospital setting. Of 1,916 vaginal hysterectomies performed, 35.0% were in the inpatient surgery hospital setting and 65.0% were in the ambulatory surgery hospital setting. Of 18,015 laparoscopic hysterectomies performed, 22.5% were in the inpatient surgery hospital setting and 77.5% were in the ambulatory surgery hospital setting. Of 9,002 open myomectomies performed, 60.6% were in the inpatient surgery hospital setting and 39.4% were in the ambulatory surgery hospital setting. Of 1,751 laparoscopic myomectomies performed, 7.0% were in the inpatient surgery hospital setting and 93.0% were in the ambulatory surgery hospital setting. Of 1,966 uterine fibroid embolizations performed, 20.1% were in the inpatient surgery hospital setting and 79.9% were in the ambulatory surgery hospital setting. Of 1,028 endometrial ablations performed, 1.8% were in the inpatient surgery hospital setting and 98.2% were in the ambulatory surgery hospital setting.
|
Figures 4 and 5 present the distribution of hospital inpatient stays and hospital-based ambulatory surgery visits for three of the four procedures—hysterectomy, myomectomy, and uterine fibroid embolization—to treat benign uterine fibroids in 2013. Endometrial ablation is not presented because very few of these procedures overall were performed in the inpatient setting. Figure 4 presents the distribution of hospital inpatient stays compared with hospital-based ambulatory surgery visits by patient race/ethnicity for three surgical procedures to treat benign uterine fibroids in 2013. |
Figure 4. Distribution of hospital setting for three surgical procedures to treat benign uterine fibroids by patient race/ethnicity, in 13 States, 2013
Source: Agency for Healthcare Research and Quality (AHRQ), Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project (HCUP), State Inpatient Databases (SID) and State Ambulatory Surgery and Services Databases (SASD) from 13 States, 2013 Figure 4 is a bar chart that shows the distribution of hospital setting for hysterectomy, myomectomy, and uterine fibroid embolization to treat benign uterine fibroids by race/ethnicity in 13 States in 2013. Among White women who underwent a hysterectomy in 2013, 46.2% underwent the procedure in the inpatient surgery hospital setting and 53.8% did so in the ambulatory surgery setting. Among Black women who underwent a hysterectomy in 2013, 65.0% underwent the procedure in the inpatient surgery hospital setting and 35.0% did so in the ambulatory surgery setting. Among Hispanic women who underwent a hysterectomy in 2013, 70.2% underwent the procedure in the inpatient surgery hospital setting and 29.8% did so in the ambulatory surgery setting. Among women of other race/ethnicity who underwent a hysterectomy in 2013, 67.3% underwent the procedure in the inpatient surgery hospital setting and 32.7% did so in the ambulatory surgery setting.
Among White women who underwent a myomectomy in 2013, 31.9% underwent the procedure in the inpatient surgery hospital setting and 68.1% did so in the ambulatory surgery setting. Among Black women who underwent a myomectomy in 2013, 63.6% underwent the procedure in the inpatient surgery hospital setting and 36.4% did so in the ambulatory surgery setting. Among Hispanic women who underwent a myomectomy in 2013, 58.1% underwent the procedure in the inpatient surgery hospital setting and 41.9% did so in the ambulatory surgery setting. Among women of other race/ethnicity who underwent a myomectomy in 2013, 59.7% underwent the procedure in the inpatient surgery hospital setting and 40.3% did so in the ambulatory surgery setting. Among White women who underwent a uterine fibroid embolization in 2013, 16.6% underwent the procedure in the inpatient surgery hospital setting and 83.4% did so in the ambulatory surgery setting. Among Black women who underwent a uterine fibroid embolization in 2013, 21.4% underwent the procedure in the inpatient surgery hospital setting and 78.6% did so in the ambulatory surgery setting. Among Hispanic women who underwent a uterine fibroid embolization in 2013, 31.0% underwent the procedure in the inpatient surgery hospital setting and 69.0% did so in the ambulatory surgery setting. Among women of other race/ethnicity who underwent a uterine fibroid embolization in 2013, 19.3% underwent the procedure in the inpatient surgery hospital setting and 80.7% did so in the ambulatory surgery setting. |
|
Figure 5. Distribution of hospital setting for three surgical procedures to treat benign uterine fibroids by expected primary payer, in 13 States, 2013
Note: Other expected primary payer includes Medicare. Figure 5 is a bar chart that shows the distribution of hospital setting for hysterectomy, myomectomy, and uterine fibroid embolization to treat benign uterine fibroids by expected primary payer in 13 States in 2013. Among patients covered by Medicaid who underwent a hysterectomy in 2013, 67.7% underwent the procedure in the inpatient surgery hospital setting and 32.3% did so in the ambulatory surgery setting. Among patients covered by private insurance who underwent a hysterectomy in 2013, 51.8% underwent the procedure in the inpatient surgery hospital setting and 48.2% did so in the ambulatory surgery setting. Among uninsured patients who underwent a hysterectomy in 2013, 73.0% underwent the procedure in the inpatient surgery hospital setting and 27.0% did so in the ambulatory surgery setting. Among patients with other insurance coverage who underwent a hysterectomy in 2013, 58.5% underwent the procedure in the inpatient surgery hospital setting and 41.5% did so in the ambulatory surgery setting.
Among patients covered by Medicaid who underwent a myomectomy in 2013, 65.4% underwent the procedure in the inpatient surgery hospital setting and 34.6% did so in the ambulatory surgery setting. Among patients covered by private insurance who underwent a myomectomy in 2013, 49.0% underwent the procedure in the inpatient surgery hospital setting and 51.0% did so in the ambulatory surgery setting. Among uninsured patients who underwent a myomectomy in 2013, 61.9% underwent the procedure in the inpatient surgery hospital setting and 38.1% did so in the ambulatory surgery setting. Among patients with other insurance coverage who underwent a hysterectomy in 2013, 51.2% underwent the procedure in the inpatient surgery hospital setting and 48.8% did so in the ambulatory surgery setting. Among patients covered by Medicaid who underwent a uterine fibroid embolization in 2013, 31.2% underwent the procedure in the inpatient surgery hospital setting and 68.8% did so in the ambulatory surgery setting. Among patients covered by private insurance who underwent a uterine fibroid embolization in 2013, 19.0% underwent the procedure in the inpatient surgery hospital setting and 81.0% did so in the ambulatory surgery setting. Among uninsured patients who underwent a uterine fibroid embolization in 2013, 22.6% underwent the procedure in the inpatient surgery hospital setting and 77.4% did so in the ambulatory surgery setting. Among patients with other insurance coverage who underwent a uterine fibroid embolization in 2013, 19.2% underwent the procedure in the inpatient surgery hospital setting and 80.8% did so in the ambulatory surgery setting. |
The volumes and rates in this Statistical Brief are based upon data from the Healthcare Cost and Utilization Project (HCUP) 2013 State Inpatient Databases (SID) and State Ambulatory Surgery and Services Databases (SASD). We used a subset of 13 inpatient and ambulatory surgery State datasets that had complete outpatient procedure coding, via International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes and/or Current Procedural Terminology (CPT®) procedure codes that included CPT modifiers: Connecticut, Indiana, Kansas, Maryland, Minnesota, Nebraska, New Jersey, New York, Ohio, South Carolina, Tennessee, Vermont, and Wisconsin. Historical data were drawn from the same 13 States in the 2005, 2007, 2009, and 2011 SID and SASD. Analysis was limited to hospitals within the 13 States that had cases of benign uterine fibroids involving four surgical procedures in the inpatient and ambulatory surgery settings in each data year. Supplemental sources included population denominator data for use with HCUP databases, derived from information available from the Nielsen Company.10 Definitions Diagnoses, procedures, ICD-9-CM, CPT® The principal diagnosis is that condition established after study to be chiefly responsible for the patient's hospital inpatient stay or outpatient visit. Secondary diagnoses are concomitant conditions that coexist at the time of the visit or admission or that develop during the stay. All-listed procedures include all procedures performed during the hospital inpatient stay or outpatient visit, whether for definitive treatment or for diagnostic or exploratory purposes. The first-listed procedure is the procedure that is listed first on the discharge record. Inpatient data define this as the principal procedure—the procedure that is performed for definitive treatment rather than for diagnostic or exploratory purposes (i.e., the procedure that was necessary to take care of a complication). Procedures on inpatient hospitalization records are coded using the ICD-9-CM; procedures on ambulatory surgery and services records can be coded using either ICD-9-CM or the CPT. ICD-9-CM assigns numeric codes to diagnoses and procedures. There are approximately 14,000 ICD-9-CM diagnosis codes and 4,000 ICD-9-CM procedure codes. CPT assigns numeric codes to procedures. There are approximately 9,600 CPT procedure codes. Case definition Hospital discharge and ambulatory surgery visit records with uterine fibroids were identified based on any of the following principal ICD-9-CM diagnosis codes:
|
Table 2. ICD-9-CM diagnosis codes for identifying female genital cancer |
||
ICD-9-CM diagnosis code | Description | |
---|---|---|
179. | Malignant neoplasm of uterus, part unspecified | |
180.0 | Malignant neoplasm of endocervix | |
180.1 | Malignant neoplasm of exocervix | |
180.8 | Malignant neoplasm of other specified sites of cervix | |
180.9 | Malignant neoplasm of cervix uteri, unspecified site | |
181. | Malignant neoplasm of placenta | |
182.0 | Malignant neoplasm of corpus uteri, except isthmus | |
182.1 | Malignant neoplasm of isthmus | |
182.8 | Malignant neoplasm of other specified sites of body of uterus | |
183.0 | Malignant neoplasm of ovary | |
183.2 | Malignant neoplasm of fallopian tube | |
183.3 | Malignant neoplasm of broad ligament of uterus | |
183.4 | Malignant neoplasm of parametrium | |
183.5 | Malignant neoplasm of round ligament of uterus | |
183.8 | Malignant neoplasm of other specified sites of uterine adnexa | |
183.9 | Malignant neoplasm of uterine adnexa, unspecified site | |
184.0 | Malignant neoplasm of vagina | |
184.1 | Malignant neoplasm of labia majora | |
184.2 | Malignant neoplasm of labia minora | |
184.3 | Malignant neoplasm of clitoris | |
184.4 | Malignant neoplasm of vulva, unspecified site | |
184.8 | Malignant neoplasm of other specified sites of female genital organs | |
184.9 | Malignant neoplasm of female genital organ, site unspecified | |
233.1 | Carcinoma in situ of cervix uteri | |
233.2 | Carcinoma in situ of other and unspecified parts of uterus | |
233.3 | Carcinoma in situ, unspecified female genital, not elsewhere classified | |
233.30 | Carcinoma in situ, unspecified female genital organ | |
233.31 | Carcinoma in situ, vagina | |
233.32 | Carcinoma in situ, vulva | |
233.39 | Carcinoma in situ, other female genital organ | |
236.0 | Neoplasm of uncertain behavior of uterus | |
236.1 | Neoplasm of uncertain behavior of placenta | |
236.2 | Neoplasm of uncertain behavior of ovary | |
236.3 | Neoplasm of uncertain behavior of other and unspecified female genital organs | |
The population used in this Statistical Brief was females aged 18-54 years. Uterine fibroids become more common as women age but shrink after menopause; they are most common among women in their 40s and early 50s.11 Analysis was limited to hospital discharge or ambulatory surgery visit records with (1) a principal diagnosis of uterine fibroids, (2) no secondary diagnosis of female genital cancer, and (3) one of four primary surgical procedures to treat uterine fibroids: hysterectomy, myomectomy, uterine fibroid embolization, and endometrial ablation. These surgical procedures are the most common surgical treatments for benign uterine fibroids. These procedures were defined based on all-listed procedure codes as identified using the ICD-9-CM and CPT procedure codes in Table 3. Procedures were ranked hierarchically, as shown in Table 3, so that each hospital discharge or ambulatory surgery visit record was identified with only one type of procedure.
|
Table 3. ICD-9-CM and CPT procedure codes for defining procedures to treat uterine fibroids |
|||
Procedure | ICD-9-CM procedure codes | CPT codes | |
---|---|---|---|
Hysterectomya | Open (abdominal) |
|
|
Vaginal |
|
|
|
Laparoscopicc |
|
|
|
Myomectomy | Opene |
|
|
Laparoscopicc |
|
|
|
Uterine fibroid embolization |
|
|
|
Endometrial ablation |
|
|
|
a Radical hysterectomy (ICD-9-CM 68.61, 68.69, 68.71, and 68.79, and CPT 58210, 58285, 58548) and unspecified hysterectomy (ICD-9-CM 68.9) were not included in this analysis. b ICD-9-CM code 68.4 was used prior to 10/1/06 and does not directly allow the distinction of open versus laparoscopic hysterectomy. The code was invalid after 10/1/06 when 68.41 and 68.49 came into use. c Laparoscopic includes both abdominal and vaginal approaches. d CPT codes 58578 and 37204 are not specific to hysterectomy or uterine fibroid embolization; these require the uterine fibroid diagnosis in order to link them to these procedures. e Open myomectomy includes CPT 58145 for vaginal myomectomy. |
Types of hospitals included in HCUP State Inpatient Databases This analysis used State Inpatient Databases (SID) limited to data from community hospitals, which are defined as short-term, non-Federal, general, and other hospitals, excluding hospital units of other institutions (e.g., prisons). Community hospitals include obstetrics and gynecology, otolaryngology, orthopedic, cancer, pediatric, public, and academic medical hospitals. Excluded for this analysis are long-term care facilities such as rehabilitation, psychiatric, and alcoholism and chemical dependency hospitals. However, if a patient received long-term care, rehabilitation, or treatment for psychiatric or chemical dependency conditions in a community hospital, the discharge record for that stay was included in the analysis. The analysis was limited to hospitals that had at least one uterine fibroid procedure performed in both the SID and SASD in each data year. Types of hospitals included in HCUP State Ambulatory Surgery and Services Databases This analysis used State Ambulatory Surgery and Services Databases (SASD) limited to data from hospital-owned ambulatory surgery facilities. Although some SASD include data from facilities not owned by a hospital, those facilities were excluded from this analysis. The designation of a facility as hospital-owned is specific to its financial relationship with a hospital that provides inpatient care and is not related to its physical location. Ambulatory surgery performed in hospital-owned facilities may be performed within the hospital, in a facility attached to the hospital, or in a facility physically separated from the hospital. The analysis was further limited to ambulatory surgeries performed at facilities owned by community hospitals. Community hospitals are defined as short-term, non-Federal, general, and other specialty hospitals, excluding hospital units of other institutions (e.g., prisons). The analysis was limited to hospitals that had at least one uterine fibroid procedure performed in both the SID and SASD in each data year. Unit of analysis The unit of analysis is the hospital discharge (i.e., the hospital stay) for an inpatient stay or ambulatory surgery visit, not a person or patient. This means that a person who is admitted to the hospital to have surgery multiple times in 1 year will be counted each time as a separate discharge from the hospital or visit. Charges Charges represent what the hospital billed for the discharge. Hospital charges reflect the amount the hospital charged for the entire hospital stay and do not include professional (physician) fees. We report hospital charges rather than costs because Cost-to-Charge Ratios are not available for ambulatory surgery data. Median community-level income Median community-level income is the median household income of the patient's ZIP Code of residence. Income levels are separated into population-based quartiles with cut-offs determined using ZIP Code demographic data obtained from the Nielsen Company. Patients in the first quartile are designated as having low income, and patients in the upper three quartiles are designated as having not low income. The income quartile is missing for patients who are homeless or foreign. Payer Payer is the expected payer for the hospital stay. To make coding uniform across all HCUP data sources, payer combines detailed categories into general groups:
Reporting of race and ethnicity Data on Hispanic ethnicity are collected differently among the States and also can differ from the Census methodology of collecting information on race (White, Black, Asian/Pacific Islander, American Indian/Alaska Native, Other (including mixed race)) separately from ethnicity (Hispanic, non-Hispanic). State data organizations often collect Hispanic ethnicity as one of several categories that include race. Therefore, for multistate analyses, HCUP creates the combined categorization of race and ethnicity for data from States that report ethnicity separately. When a State data organization collects Hispanic ethnicity separately from race, HCUP uses Hispanic ethnicity to override any other race category to create a Hispanic category for the uniformly coded race/ethnicity data element, while also retaining the original race and ethnicity data. All of the States included in the analyses for this Statistical Brief report Hispanic ethnicity. This Statistical Brief reports race/ethnicity for the following categories: Hispanic, non-Hispanic White, non-Hispanic Black, non-Hispanic Other (includes Asian/Pacific Islander, American Indian/Alaska Native, and Other). About HCUP The Healthcare Cost and Utilization Project (HCUP, pronounced "H-Cup") is a family of healthcare databases and related software tools and products developed through a Federal-State-Industry partnership and sponsored by the Agency for Healthcare Research and Quality (AHRQ). HCUP databases bring together the data collection efforts of State data organizations, hospital associations, and private data organizations (HCUP Partners) and the Federal government to create a national information resource of encounter-level healthcare data. HCUP includes the largest collection of longitudinal hospital care data in the United States, with all-payer, encounter-level information beginning in 1988. These databases enable research on a broad range of health policy issues, including cost and quality of health services, medical practice patterns, access to healthcare programs, and outcomes of treatments at the national, State, and local market levels. HCUP would not be possible without the contributions of the following data collection Partners from across the United States: Alaska State Hospital and Nursing Home Association Arizona Department of Health Services Arkansas Department of Health California Office of Statewide Health Planning and Development Colorado Hospital Association Connecticut Hospital Association District of Columbia Hospital Association Florida Agency for Health Care Administration Georgia Hospital Association Hawaii Health Information Corporation Illinois Department of Public Health Indiana Hospital Association Iowa Hospital Association Kansas Hospital Association Kentucky Cabinet for Health and Family Services Louisiana Department of Health and Hospitals Maine Health Data Organization Maryland Health Services Cost Review Commission Massachusetts Center for Health Information and Analysis Michigan Health & Hospital Association Minnesota Hospital Association Mississippi Department of Health Missouri Hospital Industry Data Institute Montana MHA - An Association of Montana Health Care Providers Nebraska Hospital Association Nevada Department of Health and Human Services New Hampshire Department of Health & Human Services New Jersey Department of Health New Mexico Department of Health New York State Department of Health North Carolina Department of Health and Human Services North Dakota (data provided by the Minnesota Hospital Association) Ohio Hospital Association Oklahoma State Department of Health Oregon Association of Hospitals and Health Systems Oregon Office of Health Analytics Pennsylvania Health Care Cost Containment Council Rhode Island Department of Health South Carolina Revnue and Fiscal Affairs Office South Dakota Association of Healthcare Organizations Tennessee Hospital Association Texas Department of State Health Services Utah Department of Health Vermont Association of Hospitals and Health Systems Virginia Health Information Washington State Department of Health West Virginia Health Care Authority Wisconsin Department of Health Services Wyoming Hospital Association About Statistical Briefs HCUP Statistical Briefs are descriptive summary reports presenting statistics on hospital inpatient and emergency department use and costs, quality of care, access to care, medical conditions, procedures, patient populations, and other topics. The reports use HCUP administrative healthcare data. About the SID The HCUP State Inpatient Databases (SID) are hospital inpatient databases from data organizations participating in HCUP. The SID contain the universe of the inpatient discharge abstracts in the participating HCUP States, translated into a uniform format to facilitate multistate comparisons and analyses. Together, the SID encompass more than 95 percent of all U.S. community hospital discharges. The SID can be used to investigate questions unique to one State, to compare data from two or more States, to conduct market-area variation analyses, and to identify State-specific trends in inpatient care utilization, access, charges, and outcomes. About the SASD The HCUP State Ambulatory Surgery and Services Databases (SASD) include encounter-level data for ambulatory surgeries and may also include various types of outpatient services such as observation stays, lithotripsy, radiation therapy, imaging, chemotherapy, and labor and delivery. The specific types of ambulatory surgery and outpatient services included in each SASD vary by State and data year. All SASD include data from hospital-owned ambulatory surgery facilities. In addition, some States include data from facilities not owned by a hospital. The designation of a facility as hospital-owned is specific to its financial relationship with a hospital that provides inpatient care and is not related to its physical location. Hospital-owned ambulatory surgery and other outpatient care facilities may be contained within the hospital, physically attached to the hospital, or located in a different geographic area. This analysis was restricted to hospital-owned ambulatory surgery facilities. For More Information For more information about HCUP, visit http://www.hcup-us.ahrq.gov/. For additional HCUP statistics, visit HCUPnet, our interactive query system, at https://datatools.ahrq.gov/hcupnet. For information on other hospitalizations in the United States, refer to the following HCUP Statistical Briefs located at http://www.hcup-us.ahrq.gov/reports/statbriefs/statbriefs.jsp:
Agency for Healthcare Research and Quality. Overview of the State Inpatient Databases (SID). Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. Updated November 2014. http://www.hcup-us.ahrq.gov/sidoverview.jsp. Accessed January 7, 2015. Agency for Healthcare Research and Quality. Overview of the State Ambulatory Surgery and Services Databases (SASD). Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. Updated November 2014. http://www.hcup-us.ahrq.gov/sasdoverview.jsp. Accessed January 7, 2015. Suggested Citation Barrett ML (M.L. Barrett, Inc.), Weiss AJ (Truven Health Analytics), Stocks C (AHRQ), Steiner CA (AHRQ), Myers ER (Duke University Medical Center). Procedures to Treat Benign Uterine Fibroids in Hospital Inpatient and Hospital-Based Ambulatory Surgery Settings, 2013. HCUP Statistical Brief #200. January 2016. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb200-Procedures-Treat-Uterine-Fibroids.pdf. Acknowledgments The authors would like to acknowledge the contributions of Minya Sheng of Truven Health Analytics and Anne Casto of Ohio State University. *** AHRQ welcomes questions and comments from readers of this publication who are interested in obtaining more information about access, cost, use, financing, and quality of healthcare in the United States. We also invite you to tell us how you are using this Statistical Brief and other HCUP data and tools, and to share suggestions on how HCUP products might be enhanced to further meet your needs. Please e-mail us at hcup@ahrq.gov or send a letter to the address below:Virginia Mackay-Smith, Acting Director Center for Delivery, Organization, and Markets Agency for Healthcare Research and Quality 5600 Fishers Lane Rockville, MD 20857 1 Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology. 2003;188(1):100-7. 2 Office on Women's Health. Uterine Fibroids Fact Sheet. January 15, 2015. www.womenshealth.gov/a-z-topics/uterine-fibroids. Accessed October 27, 2021. 3 Ibid. 4 Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Seminars in Reproductive Medicine. 2013;31(5):370-9. 5 Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health. 2013;22(10):807-16. 6 Catherino et al., 2013. Op. cit. 7 Laughlin SK, Stewart EA. Uterine leiomyomas: individualizing the approach to a heterogeneous condition. Obstet Gynecol. 2011;117(2 Pt 1);396-403. 8 Moorman PG, Leppert P, Myers ER, Wang F. Comparison of characteristics of fibroids in African American and white women undergoing pre-menopausal hysterectomy. Fertil Sterility. 2013;99(3);768-76. 9 Office on Women's Health, January 15, 2015. Op. cit. 10 Barrett M, Lopez-Gonzalez L, Coffey R, Levit K. Population Denominator Data for Use with the HCUP Databases (Updated with 2013 Population Data). HCUP Methods Series Report #2014-02. August 18, 2014. U.S. Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/reports/methods/2014-02.pdf. Accessed January 7, 2015. 11 Office on Women's Health. Uterine Fibroids Fact Sheet. January 15, 2015. http://www.womenshealth.gov/publications/our-publications/fact-sheet/uterine-fibroids.html. Accessed July 2, 2015. |
Internet Citation: Statistical Brief #200. Healthcare Cost and Utilization Project (HCUP). January 2016. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb200-Procedures-Treat-Uterine-Fibroids.jsp. |
Are you having problems viewing or printing pages on this website? |
If you have comments, suggestions, and/or questions, please contact hcup@ahrq.gov. |
Privacy Notice, Viewers & Players |
Last modified 1/12/16 |